Our board members are public health and business leaders from the countries we serve and the United States. The board provides governance and fiduciary oversight, sets policy, and assesses PATH's overall performance. We are extremely grateful for their dedication and contribution to our work.
- Jo Addy
- Dean Allen
- Peggy Johnson
- David King
- Gary Locke
- Bruce McNamer
- Felix Olale
- Deanna Oppenheimer
- John-Arne Røttingen
- Dennis Schmatz
- Ireena Vittal
- Yehong Zhang
Jo Addy, MBA, MPA
Jo Addy, MBA, MPA, is a veteran corporate strategist and international economist. She is the founder and managing director of Alsweb Business Advantage, which designs strategic platforms for global for-profit and nonprofit clients. Ms. Addy has implemented business development initiatives worldwide, and she has developed systems and metrics to monitor political and business risk for World Bank and international bank portfolios.
Ms. Addy previously served as vice president for administration and communications for Plebys International, helping to secure $40 million in social capital for clean water technologies that reached 3 million people. She also founded UniMed Ventures Inc., a medical supply distributorship in Accra, Ghana. Ms. Addy has led numerous boards and volunteers for the American Red Cross as a regional lead for international humanitarian law dissemination and a supervising specialist for disaster logistics.
Ms. Addy earned an MBA from Adelphi University in New York and a MPA with specialization in corporate governance from the Harvard Kennedy School. A graduate of Smith College, she achieved doctoral candidacy in economics at Stanford University.
Dean Allen is chief executive officer of McKinstry, a design/build mechanical and electrical firm headquartered in Seattle. Mr. Allen has more than 35 years of experience in the design, construction, and real estate industries in the Pacific Northwest. Under his leadership, McKinstry has grown from a mechanical contractor into a comprehensive design, build, operate, and maintain enterprise with more than $500 million per year in revenues and more than 1,800 employees. A leader in the energy and sustainability aspects of the industry, McKinstry serves energy service clients from 21 offices located across the Midwest and Western United States.
Mr. Allen has served the community in a variety of industry and philanthropic roles. Beyond his board role at PATH, he currently sits on the boards of Seattle Children’s Hospital, where he is chair of the Research Institute Advisory Board; Global Partnerships; and Washington STEM. He also serves on the Washington Roundtable and the Partnership for Learning.
Mr. Allen earned BS degrees in molecular biology and psychology from the University of Washington, where he graduated magna cum laude.
Peggy Johnson is the executive vice president of business development at Microsoft, responsible for driving strategic partnerships and transactions to accelerate growth for Microsoft and its customers. She works with external partners around the world, ranging from start-ups to large-scale enterprises, to identify areas of collaboration, drive innovation and unlock shared value. In this capacity, she also manages Microsoft’s relationship with the venture capital community and oversees strategic investments through the company’s corporate venture fund, Microsoft Ventures.
Prior to this role, Ms. Johnson spent 24 years at Qualcomm, where she served as a member of Qualcomm’s Executive Committee. During her time at Qualcomm, she held various leadership positions across engineering, sales, marketing, and business development, and she ran the Qualcomm Internet Services business unit. Most recently, Ms. Johnson was executive vice president of Qualcomm Technologies, Inc., and president of global market development, where she was responsible for commercializing new business opportunities and developing strategic relationships for the company.
Ms. Johnson earned her bachelor’s degree in electrical engineering from San Diego State University. She represents the United States on the Asia-Pacific Economic Cooperation Business Advisory Council and serves as a board member for Live Nation Entertainment, Inc.
David King, JD
David King, JD, is the chairman and chief executive officer of Laboratory Corporation of America Holdings (LabCorp), one of the world’s largest networks of clinical laboratories. Prior to joining LabCorp in 2001, Mr. King worked for many years as the company’s outside counsel as a partner with Hogan & Hartson LLP (now HoganLovells) in Baltimore, Maryland.
Mr. King sits on the board of Cardinal Health, Inc., a Fortune 100 healthcare company. He also chairs the board of the American Clinical Laboratory Association and serves on the board of the Seattle Science Foundation.
Mr. King earned a JD degree from the University of Pennsylvania Law School and an AB degree from Princeton University.
Gary Locke, JD
Gary Locke, JD, is chairman of Locke Global Strategies LLC, advising US and Chinese companies on cross-border trade and investment. He is also a senior advisor for the Seattle-based law firm of Davis Wright Tremaine, consulting with domestic and international clients.
Mr. Locke served as the US ambassador to the People’s Republic of China from 2011 to 2014 and as secretary of commerce 2009 to 2011. Before his appointment to President Obama’s Cabinet, he served two terms as governor of Washington State.
Governor Locke has been a longtime leader in education, employment, trade, health care, human rights, immigration reform, privacy, and the environment. He is the first Chinese American to serve as ambassador to China, as secretary of commerce, and as a governor.
Governor Locke holds a law degree from Boston University and a bachelor’s degree in political science from Yale University.
Bruce McNamer, JD, MBA
Bruce McNamer, JD, MBA, is the president and chief executive officer of The Community Foundation for the National Capital Region, a tax-exempt public charity that is dedicated to improving the Greater Washington region by connecting caring people to causes that matter. The foundation, which serves the District of Columbia, Montgomery County, Prince George’s County, and Northern Virginia, currently manages more than 700 donor funds with assets totaling more than $350 million. The foundation is the largest local funder of nonprofit organizations in the region and is one of the larger foundations of its kind in the United States.
Mr. McNamer joined The Community Foundation in 2015, bringing broad experience in the public, private, and philanthropic sectors. From 2013 to 2014, he was the head of Global Philanthropy and CEO of the JPMorgan Chase Foundation. Prior to that, he served as the president and CEO of TechnoServe, a nonprofit organization that works with people in the developing world to build competitive farms, businesses, and industries, with operations in 30 countries in Africa, Latin America, and India. Before joining TechnoServe in 2004, Mr. McNamer was a senior executive and founder of technology start–ups, an investment banker at Morgan Stanley, and a management consultant at McKinsey & Company. Bruce was also a White House Fellow at the National Economic Council and a Peace Corps volunteer in Paraguay.
Mr. McNamer earned a JD and an MBA from Stanford and an AB from Harvard. He is a member of the Council on Foreign Relations.
Felix Olale, MD, PhD
Felix Olale, MD, PhD, is a partner in LeapFrog Investments. An entrepreneur, innovator, physician-scientist, and advisor, Dr. Olale is known for his work building businesses and investing in health care in emerging markets. He has led and advised on transactions of more than US$100 million in financing across Africa and holds a number of board appointments, including chairing PATH’s governance committee and the advisory board of the Institute for Healthcare Management at Strathmore Business School in Nairobi.
Prior to LeapFrog, Dr. Olale was executive chairman of the Excelsior Group, a US- and Kenya-based advisor in emerging markets. While at Excelsior, he cofounded Wellness Group, an East African specialty consultation and medical diagnostics company. Dr. Olale is also a founding member of the Healthcare Advisory Board for Safaricom, the leading Kenyan telecommunications and mobile money operator.
Dr. Olale began his career at Skirball Institute of Bio-molecular Medicine in New York, where he cloned two genes involved in organ patterning and regeneration. He also worked as a venture capital analyst at New York University’s Office of Industrial Liaison and Applied Research Fund and as an associate partner and a leader in the pharmaceutical, medical products, and global health practices at McKinsey & Company in New York.
Dr. Olale received his medical and doctorate degrees from New York University School of Medicine and a BA in molecular biology from the University of Pennsylvania.
Deanna Oppenheimer is the founder of CameoWorks, LLC, a global firm that advises leaders of early stage companies and consultancies. From 2005–2011, she served in a number of roles at Barclays PLC, first as chief executive of UK Retail and Business Banking and then as vice chair of Global Retail Banking. From 1985–2005, she served in a number of positions at Washington Mutual, Inc., with her last role as president of Consumer Banking, where she helped to transform the lender from a regional to a national player.
Ms. Oppenheimer's board roles include chair of Hargreaves Lansdown, a FTSE 100 financial services company. She also serves currently and has served in the past on several public and private fiduciary and advisory boards in the UK, France, and the US. Her work as a board director in the public, private, and nonprofit sectors prompted her to create BoardReady.io, a technology platform powered by Vettd to advance board diversity.
Ms. Oppenheimer graduated with honors from University of Puget Sound in Washington State and attended the executive education program at Northwestern University's Kellogg School of Management in Illinois.
Professor John-Arne Røttingen, MD, PhD, MSc, MPA, is the chief executive of the Research Council of Norway and adjunct professor at the Department of Global Health and Population, Harvard T.H. Chan School of Public Health. He was until recently the founding interim chief executive officer of CEPI (Coalition for Epidemic Preparedness Innovations); executive director of Infection Control and Environmental Health at the Norwegian Institute of Public Health; and professor of health policy at the Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo. He is associate fellow at the Centre on Global Health Security, Chatham House, and member of the WHO Euro Advisory Committee on Health Research.
Dr. Røttingen received his MD and PhD from the University of Oslo, an MSc from Oxford University, and an MPA from Harvard University.
Dennis Schmatz, PhD
Dennis Schmatz, PhD, has more than 35 years of drug discovery and development experience in pharmaceutical research, including infectious diseases, oncology, and diabetes. He served as vice president of Infectious Disease Research and Animal Health at Merck & Co., Inc. for more than a decade, managed international research programs as the head of the Merck research site in Japan, and was responsible for pharmaceutical research programs located in the United States, Spain, and Canada.
Dr. Schmatz has participated in global health initiatives for more than 30 years, working with organizations such as the World Health Organization (WHO), Medicines for Malaria Venture (MMV), Bill & Melinda Gates Foundation, and Global Health Innovation Technology Fund. In 2010, he served as the interim CEO of MMV and currently serves as the chairman of the Board and president of MMV North America. He chairs the MMV Scientific Board and also consults for global health organizations, biotech, and pharmaceutical companies.
Dr. Schmatz has contributed to the discovery of new biochemical pathways and drug targets, novel natural products with antimicrobial activity, and several approved drugs, including Cancidas (an antifungal agent for treating serious life-threatening hospital infections), Invanz (a carbapenem antibiotic for moderate to severe infections), Zactran (an antibiotic for bovine respiratory disease in cattle), SCY-078 (an IV/oral antifungal agent currently in phase 2 clinical trials at Scynexis Inc.), Previcox (an analgesic for companion animals), and Gastroguard (a proton pump inhibitor for horses).
Dr. Schmatz received a PhD in biology/biochemistry, and MS in biology/biochemistry/cell biology, and a BS in preveterinary medicine, all from Rutgers University.
Ireena Vittal, MBA
Ireena Vittal, MBA, has significant expertise in emerging markets, Indian agriculture, and urbanization. She has contributed in a variety of private-sector roles, most recently as partner at McKinsey & Co., where she was a founding member of both the economic development and global emerging markets practices. Prior to her 16-year tenure at McKinsey, Vittal held positions at Max Touch (now Vodafone) and Nestlé.
Ms. Vittal is an independent advisor to a range of companies, including Godrej Consumer, AXIS Bank, Wipro Ltd., Tata Global Beverages, the Indian Hotels Company, and Titan Company, and she serves on the global advisory board of ideo.org.
Ms. Vittal received an MBA from the Indian Institute of Management, Calcutta, and a BS in electronics from Osmania University.
Yehong Zhang, PhD, MBA
Yehong Zhang, PhD, MBA, is the chief executive officer of Luye Pharmaceutical Group (International).
Formerly, Dr. Zhang served as vice president of Aetna, a leading global diversified health care solutions company. Prior to joining Aetna in 2013, he was CEO of Simcere MSD Pharmaceutical Co. Ltd, a joint venture established in 2012 between Simcere, a leading China-based pharmaceutical manufacturer, and Merck & Co., one of the world’s largest multinational drug companies. Previously, he was Simcere’s president, where he was instrumental in driving strategic partnerships with several large multinational pharmaceutical companies to serve China’s rapidly expanding health care needs.
Prior to Simcere, Dr. Zhang was a practice leader for McKinsey & Co.’s health care consultancy efforts in China, where he advised local health care companies and worked closely with government stakeholders. Earlier, he was the China president for Merck and held a similar role for IMS Health, a leading health care information, services, and technology company.
A native of China, Dr. Zhang was educated in the United States. He holds a doctorate in engineering from the University of Pennsylvania, an MBA from the Wharton School, and an undergraduate degree from Harvard University.
Photos: Dean Allen, Julia Fiset; Peggy Johnson, Inti St. Clair; David King, courtesy of LabCorp; Gary Locke, Humanature Photography; Tsitsi Masiyiwa, courtesy of Tsitsi Masiyiwa; Laurie Michaels, courtesy of Laurie Michaels; Felix Olale, Shaban Omboke; Deanna Oppenheimer, Anthony Bolante; Kevin Reilly, Julia Fiset; John-Arne Røttingen, Sverre Jarild; Ireena Vittal, courtesy of Ireena Vittal; Yehong Zhang, Aetna International; all others, PATH/Patrick McKern.